<DOC>
	<DOC>NCT02092467</DOC>
	<brief_summary>This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.</brief_summary>
	<brief_title>Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Necrosis</mesh_term>
	<mesh_term>Tofacitinib</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Moderate to severe rheumatoid arthritis Taking methotrexate without adequate control of symptoms Have at least one cardiovascular risk factor (eg, current smoker, high blood pressure, high cholesterol levels, diabetes mellitus, history of heart attack, family history of coronary heart disease, extraarticular RA disease) Current or recent infection Clinically significant laboratory abnormalities Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Post-marketing</keyword>
	<keyword>Phase 4</keyword>
	<keyword>Open-label</keyword>
	<keyword>Safety Surveillance</keyword>
	<keyword>CP690550</keyword>
	<keyword>Xeljanz</keyword>
	<keyword>oral treatment</keyword>
</DOC>